Published in Gene Therapy Weekly, April 10th, 2008
Under the terms of the agreement, AVI is issuing $7.4 million in AVI common stock valued at $1.3161 per share in exchange for all outstanding shares of Ercole stock not already owned by AVI. In addition, AVI has assumed responsibility for $1.5 million in liabilities of Ercole, to be paid by a combination of cash and AVI stock.
The Importance of RNA Splicing
Through the Human Genome Project and subsequent studies, the way in which the body controls cellular processes has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.